Case Report
Published on 28 Nov 2025
Malignant mesothelioma in rare sites: two case reports
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1698949
- 241 views
Type at least 3 characters
1,545 articles
Brief Research Report
Published on 26 Nov 2025
Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1732480
- 507 views
Original Research
Published on 26 Nov 2025
A CD47 antibody with minimized erythrocyte and thrombocyte toxicities
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1686180
- 346 views
Case Report
Published on 26 Nov 2025
Ivonescimab for EGFR-mutant lung adenosquamous carcinoma after multiline therapy: A case report
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1707096
- 323 views
Original Research
Accepted on 25 Nov 2025
Improved Survival with Phosphodiesterase-5 Inhibitor Use in Men with Male-Predominant Cancers: Real-World Large Database Study
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
- 110 views
Original Research
Published on 25 Nov 2025
The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1698857
- 345 views
Original Research
Published on 25 Nov 2025
Redox phenotype confers T cell-exclusion microenvironment and resistance to immunotherapy by suppressing STING/MDA5 expression and interferon signaling in lung cancers harboring KEAP1/STK11 mutations
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1676797
- 306 views
Review
Accepted on 24 Nov 2025
CD39+PD-1+ Regulatory T Cells in Melanoma: Key Drivers of Systemic Immunosuppression and Prognostic Biomarkers
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
- 116 views
Original Research
Accepted on 24 Nov 2025
Activation of the STING pathway potentiates the antitumor efficacy of doxorubicin in soft-tissue sarcoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
- 141 views
Case Report
Accepted on 24 Nov 2025
Eribulin and Sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
- 119 views
Original Research
Published on 24 Nov 2025
Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1716014
- 442 views
Original Research
Published on 24 Nov 2025
Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1704442
- 288 views
Review
Accepted on 21 Nov 2025
Interaction of intratumoral microbiota with the tumor immune microenvironment and its impact on cancer progression
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
Original Research
Published on 21 Nov 2025
Clinical features and HLA typing of immune checkpoint inhibitor-associated myasthenia gravis, myocarditis and myositis
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1646231
- 566 views
Original Research
Published on 21 Nov 2025
Frailty trajectories and their determinants in cancer patients undergoing immunotherapy: a prospective longitudinal study
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1684827
- 301 views
Case Report
Published on 20 Nov 2025
Sintilimab combined with chemotherapy in advanced pulmonary epithelioid hemangioendothelioma: a case report and translational insights
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1575039
- 401 views